BRIVEKIMIG

UNII:	XX2BGT8CLL
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	BRIVEKIMIG
GSRS Full Record:	XX2BGT8CLL i

2834733-45-6
BRIVEKIMIG [USAN]
Brivekimig
Brivekimig [WHO-DD]
F-027300252
F027300252
IG single chain VH-VH-VH'-VH''-VH' (1-630) [VH anti-TNFSF4 Vicpac/Homsap (Vicugna pacos IGHV3-3*01 (89.8%) -(IGHD) -IGHJ7*01 (92.3%) K120>Q (116)/Homo sapiens IGHV3-23*04 (82.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.8.16] (26-34.52-59.98-113)) (1-124) -9-mer (tetraglycyl-seryl-triglycyl-seryl) linker (125-133) -VH anti-TNFSF4 Vicpac/Homsap (Vicugna pacos IGHV3-3*01 (88.9%) -(IGHD) -IGHJ7*01 (92.3%) K120>Q (249)/Homo sapiens IGHV3-23*04 (83.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.8.16] (159-167.185-192.231-246)) (134-257) -9-mer (tetraglycyl-seryl-triglycyl-seryl) linker (258-266) -VH anti-TNF (Homo sapiens IGHV3-20*04 (87.8%) -(IGHD) -IGHJ1*01 (91.9%) W118>R (371), CDR-IMGT [8.8.8] (292-299.317-324.363-370)) (267-381) -9-mer (tetraglycyl-seryl-triglycyl-seryl) linker (382-390) -VH anti-ALB (Homo sapiens IGHV3-23*04 (88.5%) -(IGHD) -IGHJ1*01 (81.8%) W118>S (495), G119>S (496), CDR-IMGT [8.8.8] (416-423.441-448.487-494)) (391-505) -9-mer (tetraglycyl-seryl-triglycyl-seryl) linker (506-514) -VH anti-TNF (Homo sapiens IGHV3-20*04 (87.8%) -(IGHD) -IGHJ1*01 (90.0%) W118>R (619), CDR-IMGT [8.8.18] (540-547.565-572.611-618)) (515-630)], produced in the yeast Pichia pastoris (Komagataella phaffii), non-glycosylated
Immunoglobulin, bispecific, pentavalent, anti-(human CD252 antigen) (human-Camelidea monoclonal 1E07 single-domain VHH fragment) fusion protein with peptide linker (G(GGGS)2) fusion protein with anti-(human CD252 antigen) (human-Camelidea monoclonal 1E07 single-domain VHH fragment) fusion protein with peptide linker (G(GGGS)2) fusion protein with anti-(human tumor necrosis factor-α) (human-Camelidea monoclonal 1C02 single-domain VHH fragment) fusion protein with peptide linker (G(GGGS)2) fusion protein with anti-(human serum albumin) (human-Camelidea monoclonal ALB single-domain VHH fragment) fusion protein with peptide linker (G(GGGS)2) fusion protein with anti-(human tumor necrosis factor-α) (human-Camelidea monoclonal 1C02 single-domain VHH fragment)
SAR-442970
SAR442970
brivekimig [INN]
immunoglobulin IG single chain of 5 VH (VH-VH-VH'-VH''-VH') monomer, anti-[Homo sapiens TNFSF4 (TNF superfamily member 4, tumor necrosis factor superfamily member 4, OX40 ligand, OX40L, TAX transcriptionallyactivated glycoprotein 1, TXGP1, gp34, CD252)], anti-[Homo sapiens TNF(tumor necrosis factor, TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA)] and anti-[Homo sapiens ALB (albumin, human serum albumin, HSA)], monoclonal antibody VH-VH-VH'-VH''-VH', trispecific, pentavalent

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

BRIVEKIMIG

Synonyms and Mappings

Resources